JP6768633B2 - 自己免疫疾患を治療するために調節性ｔ細胞を選択的に活性化する分子 - Google Patents

自己免疫疾患を治療するために調節性ｔ細胞を選択的に活性化する分子 Download PDF

Info

Publication number
JP6768633B2
JP6768633B2 JP2017504096A JP2017504096A JP6768633B2 JP 6768633 B2 JP6768633 B2 JP 6768633B2 JP 2017504096 A JP2017504096 A JP 2017504096A JP 2017504096 A JP2017504096 A JP 2017504096A JP 6768633 B2 JP6768633 B2 JP 6768633B2
Authority
JP
Japan
Prior art keywords
terminus
protein
domain
seq
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017504096A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017527272A5 (cg-RX-API-DMAC7.html
JP2017527272A (ja
Inventor
ジェフリー グレーブ，
ジェフリー グレーブ，
Original Assignee
デリニア， インコーポレイテッド
デリニア， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55163946&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6768633(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by デリニア， インコーポレイテッド, デリニア， インコーポレイテッド filed Critical デリニア， インコーポレイテッド
Publication of JP2017527272A publication Critical patent/JP2017527272A/ja
Publication of JP2017527272A5 publication Critical patent/JP2017527272A5/ja
Application granted granted Critical
Publication of JP6768633B2 publication Critical patent/JP6768633B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2017504096A 2014-07-21 2015-07-20 自己免疫疾患を治療するために調節性ｔ細胞を選択的に活性化する分子 Expired - Fee Related JP6768633B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461999241P 2014-07-21 2014-07-21
US61/999,241 2014-07-21
PCT/US2015/041177 WO2016014428A2 (en) 2014-07-21 2015-07-20 Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020147441A Division JP2021006038A (ja) 2014-07-21 2020-09-02 自己免疫疾患を治療するために調節性ｔ細胞を選択的に活性化する分子

Publications (3)

Publication Number Publication Date
JP2017527272A JP2017527272A (ja) 2017-09-21
JP2017527272A5 JP2017527272A5 (cg-RX-API-DMAC7.html) 2018-08-02
JP6768633B2 true JP6768633B2 (ja) 2020-10-14

Family

ID=55163946

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017504096A Expired - Fee Related JP6768633B2 (ja) 2014-07-21 2015-07-20 自己免疫疾患を治療するために調節性ｔ細胞を選択的に活性化する分子
JP2020147441A Pending JP2021006038A (ja) 2014-07-21 2020-09-02 自己免疫疾患を治療するために調節性ｔ細胞を選択的に活性化する分子

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020147441A Pending JP2021006038A (ja) 2014-07-21 2020-09-02 自己免疫疾患を治療するために調節性ｔ細胞を選択的に活性化する分子

Country Status (22)

Country Link
US (6) US20170037102A1 (cg-RX-API-DMAC7.html)
EP (2) EP3587444A1 (cg-RX-API-DMAC7.html)
JP (2) JP6768633B2 (cg-RX-API-DMAC7.html)
KR (1) KR102493543B1 (cg-RX-API-DMAC7.html)
CN (2) CN106795213B (cg-RX-API-DMAC7.html)
AU (3) AU2015292889C1 (cg-RX-API-DMAC7.html)
CA (1) CA2954847A1 (cg-RX-API-DMAC7.html)
DK (1) DK3172227T3 (cg-RX-API-DMAC7.html)
EA (2) EA202190903A3 (cg-RX-API-DMAC7.html)
ES (1) ES2763198T3 (cg-RX-API-DMAC7.html)
GB (1) GB2538666A (cg-RX-API-DMAC7.html)
HU (1) HUE046065T2 (cg-RX-API-DMAC7.html)
IL (3) IL289475B2 (cg-RX-API-DMAC7.html)
LT (1) LT3172227T (cg-RX-API-DMAC7.html)
MX (2) MX378790B (cg-RX-API-DMAC7.html)
PL (1) PL3172227T3 (cg-RX-API-DMAC7.html)
PT (1) PT3172227T (cg-RX-API-DMAC7.html)
RS (1) RS59789B1 (cg-RX-API-DMAC7.html)
SG (2) SG10202010158TA (cg-RX-API-DMAC7.html)
SI (1) SI3172227T1 (cg-RX-API-DMAC7.html)
WO (1) WO2016014428A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201700344B (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170028938A (ko) * 2014-07-21 2017-03-14 데리니아, 인크. 자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 분자
US12084484B2 (en) 2019-07-26 2024-09-10 Visterra, Inc. Interleukin-2 agents and uses thereof
US12098178B2 (en) 2020-12-04 2024-09-24 Visterra, Inc. Methods of using interleukin-2 agents

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3640375A3 (en) 2012-12-11 2020-07-29 Albert Einstein College of Medicine Methods for high throughput receptor/ligand identification
SI3482766T1 (sl) 2014-08-11 2020-09-30 Delinia, Inc. Spremenjene variante IL-2, ki selektivno aktivirajo regulatorne T celice za zdravljenje avtoimunskih bolezni
IL283764B2 (en) 2015-04-10 2024-01-01 Amgen Inc Interleukin-2 muteins for the expansion of t-regulatory cells
US20170204154A1 (en) * 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
KR20240115933A (ko) * 2016-05-04 2024-07-26 암젠 인크 T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
BR112018073606A2 (pt) 2016-05-18 2019-02-26 Cue Biopharma, Inc. polipeptídeos multiméricos moduladores de células t e métodos de uso dos mesmos
WO2017201131A1 (en) 2016-05-18 2017-11-23 Albert Einstein College Of Medicine, Inc. Variant pd-l1 polypeptides, t-cell modulatory multimeric polypeptides, and methods of use thereof
CA3041334A1 (en) 2016-11-08 2018-05-17 Delinia, Inc. Il-2 variants for the treatment of autoimmune diseases
JP7228515B2 (ja) * 2016-12-13 2023-02-24 デリニア，インコーポレーテッド 多価制御性ｔ細胞調節因子
WO2018119114A1 (en) 2016-12-22 2018-06-28 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
EP3596118B1 (en) 2017-03-15 2024-08-21 Cue Biopharma, Inc. Combination of multimeric fusion polypeptides and immune checkpoint inhibitor for treating hpv-associated cancer
AU2018234810B2 (en) 2017-03-15 2023-05-11 Pandion Operations, Inc. Targeted immunotolerance
CN110678550B (zh) * 2017-03-29 2023-11-14 国立大学法人宫崎大学 长效肾上腺髓质素衍生物
US10676516B2 (en) 2017-05-24 2020-06-09 Pandion Therapeutics, Inc. Targeted immunotolerance
EP3713592A4 (en) 2017-11-21 2022-01-12 The Board of Trustees of the Leland Stanford Junior University INTERLEUKIN-2 PARTIAL AGONISTS
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
MX2020005208A (es) * 2017-12-06 2020-08-20 Pandion Operations Inc Muteinas de interleucina 2 (il-2) y usos de estas.
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
IL275426B2 (en) 2017-12-19 2025-03-01 Xencor Inc Engineered il-2 fc fusion proteins
CA3086842A1 (en) 2017-12-27 2019-07-04 Kyowa Kirin Co., Ltd. Il-2 variant
EP3737689A4 (en) 2018-01-09 2021-12-01 Cue Biopharma, Inc. MULTIMERIC T CELL-MODULATING POLYPEPTIDES AND METHOD OF USING THEREOF
JP7534215B2 (ja) 2018-01-24 2024-08-14 ベイジン パーカンズ オンコロジー カンパニー リミテッド サイトカイン融合タンパク質
WO2019144309A1 (en) * 2018-01-24 2019-08-01 Beijing Percans Oncology Co. Ltd. Cytokine Fusion Proteins
EP3752178A1 (en) 2018-02-16 2020-12-23 Iltoo Pharma Use of interleukin 2 for treating sjögren's syndrome
BR112020018709A2 (pt) 2018-03-28 2021-01-05 Bristol-Myers Squibb Company Proteínas de fusão do receptor alfa de interleucina-2/interleucina-2 e métodos de uso
EP3552738B1 (en) * 2018-04-12 2024-07-31 Sandvik Machining Solutions AB A method of producing an additive manufactured object
CN120349426A (zh) 2018-06-22 2025-07-22 科优基因公司 白介素-2变体及其使用方法
WO2020007937A1 (en) 2018-07-03 2020-01-09 Iltoo Pharma Use of interleukin-2 for treating systemic sclerosis
US12459980B2 (en) 2018-07-25 2025-11-04 AskGene Pharma, Inc. IL-21 prodrugs and methods of use thereof
RU2021105821A (ru) 2018-08-06 2021-05-27 Медикайн, Инк. Соединения, связывающие рецептор il-2
ES3030707T3 (en) 2018-08-13 2025-07-01 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
KR20210107714A (ko) * 2018-12-21 2021-09-01 지앙수 헨그루이 메디슨 컴퍼니 리미티드 인간 인터류킨-2 변이체 또는 이의 유도체
WO2020160242A1 (en) 2019-02-01 2020-08-06 Regeneron Pharmaceuticals, Inc. Anti-il2 receptor gamma antigen-binding proteins
JP7570338B2 (ja) 2019-02-15 2024-10-21 インテグラル・モレキュラー・インコーポレイテッド クローディン６抗体及びその使用
WO2020168024A1 (en) 2019-02-15 2020-08-20 Integral Molecular, Inc. Antibodies comprising a common light chain and uses thereof
WO2020236875A1 (en) 2019-05-20 2020-11-26 Pandion Therapeutics, Inc. Madcam targeted immunotolerance
CA3141626A1 (en) 2019-06-12 2020-12-17 AskGene Pharma, Inc. Novel il-15 prodrugs and methods of use thereof
CA3148505A1 (en) * 2019-08-12 2021-02-18 AskGene Pharma, Inc. Novel il-2 fusion molecules
WO2021092075A1 (en) 2019-11-05 2021-05-14 Medikine Inc. IL-2RβγC BINDING COMPOUNDS
BR112022008750A2 (pt) 2019-11-05 2022-07-19 Medikine Inc Composto de ligação de receptor duplo, composição farmacêutica, método para tratar uma doença em um paciente, método para expandir células imunes, método para reforçar uma vacina, método para modificar a resposta imune e ácido nucleico
AU2020401357A1 (en) * 2019-12-12 2022-07-21 Assistance Publique - Hôpitaux De Paris Interleukin 2 chimeric constructs
IL293978A (en) * 2019-12-20 2022-08-01 Regeneron Pharma New il2 agonists and methods of using them
CA3166509A1 (en) 2020-01-14 2021-07-22 Synthekine, Inc. Biased il2 muteins methods and compositions
JP2023512687A (ja) 2020-02-03 2023-03-28 メディカイン、インコーポレイテッド ＩＬ－７Ｒα結合化合物
WO2021158623A1 (en) 2020-02-03 2021-08-12 Medikine, Inc. IL-7Rαγc BINDING COMPOUNDS
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
US11028132B1 (en) 2020-04-07 2021-06-08 Yitzhak Rosen Half-life optimized linker composition
AU2021272895A1 (en) 2020-05-12 2022-09-22 Cue Biopharma, Inc. Multimeric T-cell modulatory polypeptides and methods of use thereof
JP2023526282A (ja) 2020-05-13 2023-06-21 ボナム セラピューティクス，インク． タンパク質複合体の組成物及びその使用方法
EP4208474A2 (en) * 2020-09-01 2023-07-12 Takeda Pharmaceutical Company Limited Interleukin-2 muteins and uses thereof
EP4211149A4 (en) 2020-09-09 2024-10-09 Cue Biopharma, Inc. MULTIMERIC POLYPEPTIDES MODULATING MHC CLASS II T CELLS FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF
MX2023004598A (es) 2020-10-23 2023-06-29 Asher Biotherapeutics Inc Fusiones con moléculas de unión al antígeno cd8 para modular la función de las células inmunitarias.
AU2021369823A1 (en) 2020-10-29 2023-06-01 Bristol-Myers Squibb Company Fusion proteins for the treatment of disease
US20230398183A1 (en) 2020-11-13 2023-12-14 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition comprising human interleukin 2 variant or derivative thereof and use thereof
IL304365B2 (en) * 2021-03-31 2025-04-01 Hanmi Pharmaceutical Co Ltd A novel conjugate of an IL2 immunostimulatory analog and method of preparation thereof
US20220323607A1 (en) 2021-04-09 2022-10-13 Selecta Biosciences, Inc. Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance
IL311883A (en) 2021-10-06 2024-06-01 Assist Publique H?Pitaux De Paris Interleukin 2 chimeric constructs with targeting specificy to inflamed tissues
WO2023133319A1 (en) 2022-01-10 2023-07-13 Selecta Biosciences, Inc. High affinity il-2 receptor agonists and synthetic nanocarrier dose sparing
EP4463135A2 (en) 2022-01-10 2024-11-20 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023172628A1 (en) 2022-03-09 2023-09-14 Selecta Biosciences, Inc. Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosing
US20230372535A1 (en) 2022-03-25 2023-11-23 Selecta Biosciences, Inc. Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists and anti-igm agents
US20250222027A1 (en) 2022-04-01 2025-07-10 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
US11999771B2 (en) 2022-04-07 2024-06-04 Medikine, Inc. IL-7Rαγc ligand immunoglobulin fusion proteins
US20230381277A1 (en) 2022-04-08 2023-11-30 Selecta Biosciences, Inc. High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance
CN115322260A (zh) * 2022-06-13 2022-11-11 杭州高田生物医药有限公司 能够在肠道内富集且增殖调节性t细胞的融合蛋白及应用
JP2025530309A (ja) 2022-09-12 2025-09-11 アンスティテュー・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル・（イ・エヌ・エス・ウ・エール・エム） 自閉症スペクトラム障害の処置に使用するためのインターロイキン－２
IL319951A (en) 2022-11-30 2025-05-01 Integral Molecular Inc Antibodies targeting claudin 6, including its bispecific formats
KR20250133750A (ko) 2023-01-09 2025-09-08 오디세이 테라퓨틱스, 인코포레이티드 항-tnfr2 항원-결합 단백질 및 그의 용도
WO2024229350A1 (en) 2023-05-03 2024-11-07 Cartesian Therapeutics, Inc. Immunosuppressant in combination with high affinity il-2 receptor agonists for diabetes
WO2024229370A1 (en) 2023-05-03 2024-11-07 Cartesian Therapeutics, Inc. Compositions and methods for treating gvhd
WO2024229432A1 (en) 2023-05-03 2024-11-07 Cartesian Therapeutics, Inc. Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance
WO2024229380A1 (en) 2023-05-03 2024-11-07 Cartesian Therapeutics, Inc. Immunosuppressant in combination with high affinity il-2 receptor agonists in autoimmune liver diseases
WO2025217240A1 (en) 2024-04-10 2025-10-16 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541610B1 (en) * 1989-09-05 2003-04-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
US6955807B1 (en) 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
ATE375388T1 (de) 2001-07-27 2007-10-15 Us Gov Health & Human Serv Systeme zur stellengerichteten in-vivo-mutagenese mit oligonukleotiden
DK1454138T3 (da) * 2001-12-04 2012-02-13 Merck Patent Gmbh Immunocytokiner med moduleret selektivitet
UA87458C2 (ru) 2003-06-12 2009-07-27 Елі Ліллі Енд Компані Гибридные белки-аналоги glp-1
ES2383328T3 (es) * 2003-07-25 2012-06-20 Amgen, Inc Métodos relacionados con LDCAM y CRTAM
CN1930300A (zh) * 2004-03-05 2007-03-14 希龙公司 预测患者治疗药物耐受性的体外试验系统
RU2006135112A (ru) * 2004-03-05 2008-04-10 Чирон Корпорейшн (Us) Тест-система in vitro для прогнозирования устойчивости пациента к терапевтическим средствам
AU2007271398B2 (en) 2006-07-06 2013-06-20 Merck Patent Gmbh Compositions and methods for enhancing the efficacy of IL-2 mediated immune responses
ME02371B (me) * 2006-09-29 2016-06-20 Oncomed Pharm Inc Sastojci i postupci za dijagnstikovanje i tretman raka
JP5766124B2 (ja) * 2009-01-21 2015-08-19 アムジェン インコーポレイテッド 炎症性疾患および自己免疫疾患の処置の組成物および方法
NZ594665A (en) * 2009-03-20 2013-08-30 Genentech Inc Bispecific anti-her antibodies
CA3253628A1 (en) * 2010-03-05 2025-11-29 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
CN102174111B (zh) * 2011-01-25 2013-01-09 江苏省弗泰生物科技有限公司 人白介素2-Fc融合蛋白及其用途
HUE040326T2 (hu) * 2011-02-10 2019-03-28 Roche Glycart Ag Mutáns interleukon-2 polipeptidek
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
JP2014094898A (ja) * 2012-11-07 2014-05-22 Univ Of Tsukuba 炎症性腸疾患に関連する、ＣＤ３００ａ発現細胞の活性調節剤を含有する医薬品、ならびにＣＤ３００ａ遺伝子欠損マウスおよびＣＤ３００ａ発現細胞の活性調節剤の使用
US9546203B2 (en) * 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
DK2970486T3 (en) * 2013-03-15 2018-08-06 Xencor Inc MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS
CN103193887B (zh) * 2013-04-03 2015-02-04 江苏众红生物工程创药研究院有限公司 一种重组猪白细胞介素2-Fc融合蛋白及其编码基因和表达方法
PT3172227T (pt) 2014-07-21 2019-12-06 Delinia Inc Moléculas que ativam seletivamente células t reguladoras para o tratamento de doenças autoimuneis
US20170204154A1 (en) * 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170028938A (ko) * 2014-07-21 2017-03-14 데리니아, 인크. 자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 분자
JP2021006038A (ja) * 2014-07-21 2021-01-21 デリニア， インコーポレイテッド 自己免疫疾患を治療するために調節性ｔ細胞を選択的に活性化する分子
KR102493543B1 (ko) 2014-07-21 2023-01-30 데리니아, 인크. 자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 분자
US12084484B2 (en) 2019-07-26 2024-09-10 Visterra, Inc. Interleukin-2 agents and uses thereof
US12297249B2 (en) 2019-07-26 2025-05-13 Visterra, Inc. Interleukin-2 agents and uses thereof
US12098178B2 (en) 2020-12-04 2024-09-24 Visterra, Inc. Methods of using interleukin-2 agents

Also Published As

Publication number Publication date
ES2763198T3 (es) 2020-05-27
RS59789B1 (sr) 2020-02-28
IL278299B (en) 2022-02-01
WO2016014428A3 (en) 2016-03-24
CN106795213A (zh) 2017-05-31
EP3172227B1 (en) 2019-09-04
US20190375812A1 (en) 2019-12-12
IL250024A0 (en) 2017-03-30
KR20170028938A (ko) 2017-03-14
KR102493543B1 (ko) 2023-01-30
DK3172227T3 (da) 2019-12-02
LT3172227T (lt) 2020-02-10
EA201790213A1 (ru) 2017-06-30
PL3172227T3 (pl) 2020-04-30
EP3172227B9 (en) 2020-01-08
EA038361B1 (ru) 2021-08-13
US20170051029A1 (en) 2017-02-23
US20210047382A1 (en) 2021-02-18
MX378790B (es) 2025-03-10
AU2015292889A1 (en) 2016-01-28
AU2020203480A1 (en) 2020-06-18
CN114133456A (zh) 2022-03-04
EP3587444A1 (en) 2020-01-01
HUE046065T2 (hu) 2020-01-28
SG10202010158TA (en) 2020-11-27
AU2015292889B2 (en) 2020-02-27
SI3172227T1 (sl) 2020-02-28
EA202190903A2 (ru) 2021-07-30
PT3172227T (pt) 2019-12-06
EP3172227A2 (en) 2017-05-31
EP3172227A4 (en) 2017-12-20
GB201615553D0 (en) 2016-10-26
IL289475A (en) 2022-02-01
IL289475B1 (en) 2023-06-01
IL250024B (en) 2020-11-30
GB2538666A (en) 2016-11-23
US20220112260A1 (en) 2022-04-14
MX2021000083A (es) 2021-03-25
IL289475B2 (en) 2023-10-01
CA2954847A1 (en) 2016-01-28
EA202190903A3 (ru) 2021-12-31
US20170037102A1 (en) 2017-02-09
MX2017000821A (es) 2017-08-18
JP2021006038A (ja) 2021-01-21
US20170327555A1 (en) 2017-11-16
SG11201700514SA (en) 2017-02-27
AU2015292889C1 (en) 2023-01-19
CN106795213B (zh) 2021-12-07
AU2022204946A1 (en) 2022-07-28
ZA201700344B (en) 2020-08-26
WO2016014428A2 (en) 2016-01-28
JP2017527272A (ja) 2017-09-21

Similar Documents

Publication Publication Date Title
JP6768633B2 (ja) 自己免疫疾患を治療するために調節性ｔ細胞を選択的に活性化する分子
US11535657B2 (en) Molecules that selectively activate regulatory T cells for the treatment of autoimmune diseases
EA041387B1 (ru) Молекулы, которые избирательно активируют регуляторные t-клетки для лечения аутоиммунных заболеваний
HK1261663A1 (en) Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180622

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180622

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190425

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190424

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190716

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20190815

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20190821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190815

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190918

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191025

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200303

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200528

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200727

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200902

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200915

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200923

R150 Certificate of patent or registration of utility model

Ref document number: 6768633

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees